Matching articles for "Ebglyss"
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1749 · March 2, 2026 Free
Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only)

View the Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):e43-4 doi:10.58347/tml.2026.1749e
View the Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis
Issue 1722 · February 17, 2025
Nemolizumab (Nemluvio) for Atopic Dermatitis

Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):25-7 doi:10.58347/tml.2025.1722a
Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.
Issue 1722 · February 17, 2025 Free
Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)

View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):e1 doi:10.58347/tml.2025.1722f
View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis
Issue 1715 · November 11, 2024
Lebrikizumab (Ebglyss) for Atopic Dermatitis

The FDA has approved lebrikizumab-lbkz ( Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):179-81 doi:10.58347/tml.2024.1715b
The FDA has approved lebrikizumab-lbkz ( Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry) , another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent) , an IL-4 and IL-13 inhibitor, is approved for use in patients ≥6 months old.